Maynard Um
-
-
-
-
-
-
-
Eli Lilly: Q2 2026 IPR&D charge estimated at $3.02 per share on GAAP and non-GAAP basis
-
-
-
-
-
-
-
FDA selects 7 companies for domestic drug manufacturing pilot
-
-
-
-
-
-
-
Oral Wegovy reaches 33% of total prescriptions by May
-
-
-
-
-
-
-
Bernstein SocGen Reiterates Outperform Rating on Eli Lilly (LLY)
-
-
-
-
-
-
-
Weight Watchers integrates with Eli Lilly's LillyDirect platform
-
-
-
-
-
-
-
Lilly acquires three infectious disease companies for up to $3.83 billion
-
-
-
-
-
-
-
Eli Lilly reports weight loss data for obesity drug in older adults
-
417,306 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

